Revisiting Prei Khmeng: The Excavation of an Iron Age Settlement and Cemetery in Cambodia

Prei Khmeng, village 13 km northwest of Siem Reap, Cambodia, is noted for the presence of one of the region’s earliest monuments, Prasat Prei Khmeng. Aside from its ruined temple, Prei Khmeng is an important prehistoric occupation site that immediately pre-dates the foundation of the temple. First excavated by a Franco-Cambodian team in the early 2000s, the site was revisited in 2014 by an Australian-Cambodian research team. Recent research revealed Iron Age domestic occupation as well as inhumation burials. The burial assemblage provides evidence of regional trade and exchange and mortuary wealth differentiation. Bioarchaeological examination of the individuals interred at the site reveals intentional dental modification and perimortem blunt and sharp force skeletal trauma. This research sheds light on this important epoch in prehistory, a juncture between the prehistoric and protohistoric period in Cambodia, which was a time of substantial socio-political transformation

The excavation of Non Ban Jak, Northeast Thailand - A report on the first three seasons

Non Ban Jak is a large, moated site located in the upper Mun Valley, Northeast Thailand. Excavations over three seasons in 2011-4 have revealed a sequence of occupation that covers the final stage of the local Iron Age. The site is enclosed by two broad moats and banks, and comprises an eastern and a western mound separated by a lower intervening area. The first season opened an 8 by 8 m square on the eastern mound, while the second and third seasons uncovered part of the low terrain rising into the western mound, encompassing an area of 25 by 10 m. The former revealed a sequence of industrial, residential and mortuary activity that involved the construction of houses, kiln firing of ceramic vessels and the interment of the dead within residences. The latter involved four phases of a late Iron Age cemetery, which again incorporated house floors and wall foundations, as well as further evidence for ceramic manufacture. The excavation sheds light on a late Iron Age town occupied at the threshold of state formation

THE EXCAVATION OF PHUM SOPHY 2009-2010: AN IRON AGE SITE IN NORTH-WEST CAMBODIA

Excavations were undertaken at the village (phum) of Sophy in Banteay Meanchey Province, north-west Cambodia over two field seasons in two separate areas in 2009 and 2010. The remains of twenty individuals were found in 14 mortuary contexts with individuals interred with a range of burial goods including ceramic vessels, stone and glass beads, iron and bronze artefacts and faunal remains. The site dates to the Iron Age (dates spanning the period c. 87-526 AD) and is surrounded by the ruins of later, Pre-Angkorian temples and their associated ponds. Excavation and research has revealed Sophy to be a prehistoric agricultural village in which the inhabitants exploited a wide-range of habitats and engaged in inter-regional exchange.  The results of these investigations are presented here incorporating a description of the excavation, preliminary discussion of the material assemblage and demographic data obtained from the mortuary contexts

Secondary burial practice at megalithic jar site 1, Plain of Jars Laos

In 2020 a Lao/Australian archaeological research team revisited one of the largest megalithic jar sites in Laos, Site 1, and undertook excavations in an effort to more fully understand the ritual practice at the site. This paper reviews previous research undertaken at the site and describes the recent excavation which revealed evidence of secondary burial practice dating to the 8th to thirteenth centuries. The research confirms the use of Site 1 as a burial site where multiple individuals were interred in secondary burials in shared mortuary contexts

Dating the megalithic culture of Laos: Radiocarbon, optically stimulated luminescence and U/Pb zircon results

The megalithic jar sites of Laos (often referred to as the Plain of Jars) remain one of Southeast Asia’s most mysterious and least understood archaeological cultures. The sites, recently inscribed as UNESCO World Heritage, host hollowed stone jars, up to three metres in height, which appear scattered across the landscape, alone or clustered in groups of up to more than 400. Until now, it has not been possible to estimate when the jars were first placed on the landscape or from where the stone was sourced. Geochronological analysis using the age of detrital zircons demonstrates a likely quarry source for one of the largest megalithic jar sites. Optically Stimulated Luminescence (OSL) dating suggests the jars were positioned at the sites potentially as early as the late second millennium BC. Radiocarbon dating of skeletal remains and charcoal samples places mortuary activity around the jars from the 9-13th century AD, suggesting the sites have maintained ritual significance from the period of their initial placement until historic times

Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.

BACKGROUND: Staphylococcus aureus bacteraemia is a common cause of severe community-acquired and hospital-acquired infection worldwide. We tested the hypothesis that adjunctive rifampicin would reduce bacteriologically confirmed treatment failure or disease recurrence, or death, by enhancing early S aureus killing, sterilising infected foci and blood faster, and reducing risks of dissemination and metastatic infection. METHODS: In this multicentre, randomised, double-blind, placebo-controlled trial, adults (≥18 years) with S aureus bacteraemia who had received ≤96 h of active antibiotic therapy were recruited from 29 UK hospitals. Patients were randomly assigned (1:1) via a computer-generated sequential randomisation list to receive 2 weeks of adjunctive rifampicin (600 mg or 900 mg per day according to weight, oral or intravenous) versus identical placebo, together with standard antibiotic therapy. Randomisation was stratified by centre. Patients, investigators, and those caring for the patients were masked to group allocation. The primary outcome was time to bacteriologically confirmed treatment failure or disease recurrence, or death (all-cause), from randomisation to 12 weeks, adjudicated by an independent review committee masked to the treatment. Analysis was intention to treat. This trial was registered, number ISRCTN37666216, and is closed to new participants. FINDINGS: Between Dec 10, 2012, and Oct 25, 2016, 758 eligible participants were randomly assigned: 370 to rifampicin and 388 to placebo. 485 (64%) participants had community-acquired S aureus infections, and 132 (17%) had nosocomial S aureus infections. 47 (6%) had meticillin-resistant infections. 301 (40%) participants had an initial deep infection focus. Standard antibiotics were given for 29 (IQR 18-45) days; 619 (82%) participants received flucloxacillin. By week 12, 62 (17%) of participants who received rifampicin versus 71 (18%) who received placebo experienced treatment failure or disease recurrence, or died (absolute risk difference -1·4%, 95% CI -7·0 to 4·3; hazard ratio 0·96, 0·68-1·35, p=0·81). From randomisation to 12 weeks, no evidence of differences in serious (p=0·17) or grade 3-4 (p=0·36) adverse events were observed; however, 63 (17%) participants in the rifampicin group versus 39 (10%) in the placebo group had antibiotic or trial drug-modifying adverse events (p=0·004), and 24 (6%) versus six (2%) had drug interactions (p=0·0005). INTERPRETATION: Adjunctive rifampicin provided no overall benefit over standard antibiotic therapy in adults with S aureus bacteraemia. FUNDING: UK National Institute for Health Research Health Technology Assessment

International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways.

Primary biliary cirrhosis (PBC) is a classical autoimmune liver disease for which effective immunomodulatory therapy is lacking. Here we perform meta-analyses of discovery data sets from genome-wide association studies of European subjects (n=2,764 cases and 10,475 controls) followed by validation genotyping in an independent cohort (n=3,716 cases and 4,261 controls). We discover and validate six previously unknown risk loci for PBC (Pcombined<5 × 10(-8)) and used pathway analysis to identify JAK-STAT/IL12/IL27 signalling and cytokine-cytokine pathways, for which relevant therapies exist